These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18468582)

  • 1. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Nagase I; Hayakawa M; Shibasaki M
    Biochem Pharmacol; 2008 Jul; 76(1):98-107. PubMed ID: 18468582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.
    Someya Y; Tahara A; Nakano R; Matsuyama-Yokono A; Nagase I; Fukunaga Y; Takasu T; Hayakawa M; Shibasaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2008 May; 377(3):209-17. PubMed ID: 18398600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Pharmacol Rep; 2009; 61(5):899-908. PubMed ID: 19904014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Eur J Pharmacol; 2009 Mar; 605(1-3):170-6. PubMed ID: 19171131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Shiraki K; Hayakawa M; Shibasaki M
    Metabolism; 2009 Mar; 58(3):379-86. PubMed ID: 19217455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure.
    Someya Y; Nakano R; Tahara A; Takasu T; Takeuchi A; Nagase I; Matsuyama-Yokono A; Hayakawa M; Sasamata M; Miyata K; Uchiyama Y
    Eur J Pharmacol; 2009 Nov; 622(1-3):71-7. PubMed ID: 19766107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.
    Yasuda N; Nagakura T; Inoue T; Yamazaki K; Katsutani N; Takenaka O; Clark R; Matsuura F; Emori E; Yoshikawa S; Kira K; Ikuta H; Okada T; Saeki T; Asano O; Tanaka I
    Eur J Pharmacol; 2006 Oct; 548(1-3):181-7. PubMed ID: 16973152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel long acting DPP-IV inhibitor PKF-275-055 stimulates β-cell proliferation resulting in improved glucose homeostasis in diabetic rats.
    Akarte AS; Srinivasan BP; Gandhi S
    Biochem Pharmacol; 2012 Jan; 83(2):241-52. PubMed ID: 22015634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ASP4,000, a novel, selective, dipeptidyl peptidase 4 inhibitor with antihyperglycemic activity.
    Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Shima I; Takakura S; Muto S
    Eur J Pharmacol; 2008 Aug; 590(1-3):444-9. PubMed ID: 18582861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent.
    Takasaki K; Iwase M; Nakajima T; Ueno K; Nomoto Y; Nakanishi S; Higo K
    Eur J Pharmacol; 2004 Feb; 486(3):335-42. PubMed ID: 14985056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice.
    Tahara A; Matsuyama-Yokono A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Pharmacology; 2009; 83(3):177-87. PubMed ID: 19176982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
    Idris I; Donnelly R
    Diabetes Obes Metab; 2007 Mar; 9(2):153-65. PubMed ID: 17300591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
    Roy S; Khanna V; Mittra S; Dhar A; Singh S; Mahajan DC; Priyadarsiny P; Davis JA; Sattigeri J; Saini KS; Bansal VS
    Life Sci; 2007 Jun; 81(1):72-9. PubMed ID: 17532347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASP4000, a slow-binding dipeptidyl peptidase 4 inhibitor, has antihyperglycemic activity of long duration in Zucker fatty rats.
    Tanaka-Amino K; Matsumoto K; Hatakeyama Y; Takakura S; Mutoh S
    Acta Diabetol; 2010 Mar; 47(1):43-8. PubMed ID: 19238312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice.
    Matsuyama-Yokono A; Tahara A; Nakano R; Someya Y; Hayakawa M; Shibasaki M
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Feb; 379(2):191-9. PubMed ID: 18762913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.